Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 4/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 4/20 | 0.36 |
| ▸ | RAB9A | P51151 | 4/20 | 0.36 |
| ▸ | TACR2 | P21452 | 2/20 | 0.35 |
| ▸ | TACR1 | P25103 | 2/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23672668 | 0.98 | ADORA2A (0.42) | ADORA2ACYP3A4CYP3A5HPGDSADORA2B | |
| SCHEMBL23672860 | 0.88 | HPGDS (0.42) | ADORA2AHPGDSADORA2BNPC1RAB9A | |
| SCHEMBL23672710 | 0.86 | RAB9A (0.42) | ADORA2AHPGDSNPC1RAB9A | |
| SCHEMBL23672577 | 0.82 | CHRM1 (0.46) | ADORA2ACYP3A4CYP3A5SCN9A | |
| SCHEMBL23672636 | 0.82 | CHRM1 (0.45) | ADORA2ACYP3A4CYP3A5SCN9A | |
| SCHEMBL23672842 | 0.82 | ADORA2A (0.44) | ADORA2ACYP3A4CYP3A5ADORA2BSCN9A | |
| SCHEMBL23672618 | 0.82 | CHRM1 (0.46) | ADORA2ACYP3A4CYP3A5SCN9A | |
| SCHEMBL23673018 | 0.81 | CYP3A4 (0.48) | ADORA2ACYP3A4CYP3A5ADORA2BSCN9A | |
| SCHEMBL23672840 | 0.81 | CHRM1 (0.43) | HPGDSNPC1RAB9A | |
| SCHEMBL23673002 | 0.80 | HPGDS (0.42) | ADORA2AHPGDSADORA2BNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11111251-B2 | Positive allosteric modulators of the muscarinic acetylcholine receptor M1 | VANDERBILT UNIVERSITY (US) | 2021-09-07 | — | — | US | claimed |
| US-20210230180-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | VANDERBILT UNIVERSITY | 2021-07-29 | — | — | US | claimed |
| US-11111251-B2 | Positive allosteric modulators of the muscarinic acetylcholine receptor M1 | VANDERBILT UNIVERSITY (US) | 2021-09-07 | — | — | US | disclosed |
| US-20210230180-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | VANDERBILT UNIVERSITY | 2021-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230180-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | CHRM1, CHRM2, CHRM4 | ADORA2A 62/4885CYP3A4 1967/4885CYP3A5 3049/4885 |
| US-11111251-B2 | Positive allosteric modulators of the muscarinic acetylcholine receptor M1 | CHRM1, CHRM2, CHRM4 | ADORA2A 62/4885CYP3A4 1967/4885CYP3A5 3049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.